Could Atossa Genetics Inc (NASDAQ:ATOS) Skyrocket? The Stock Has Too Many Sellers

March 18, 2018 - By Henry Gaston

 Could Atossa Genetics Inc (NASDAQ:ATOS) Skyrocket? The Stock Has Too Many Sellers

The stock of Atossa Genetics Inc (NASDAQ:ATOS) registered an increase of 34.67% in short interest. ATOS’s total short interest was 2.05M shares in March as published by FINRA. Its up 34.67% from 1.52M shares, reported previously. With 11.90M shares average volume, it will take short sellers 0 days to cover their ATOS’s short positions.

The stock increased 8.82% or $0.045 during the last trading session, reaching $0.555. About 1.78 million shares traded. Atossa Genetics Inc. (NASDAQ:ATOS) has declined 86.91% since March 18, 2017 and is downtrending. It has underperformed by 103.61% the S&P500.

Atossa Genetics Inc. a clinical-stage pharmaceutical company, focuses on the development and sale of novel therapeutics and delivery methods for the treatment of breast cancer and other breast conditions in the United States. The company has market cap of $17.66 million. The firm is conducting a Phase II clinical study using microcatheters to deliver fulvestrant as a potential treatment of ductal carcinoma in-situ and breast cancer; and a pharmaceutical program under development is Endoxifen, an active metabolite of tamoxifen for post-breast cancer and preventative therapy, as well as a potential therapy for breast density and other breast health conditions. It currently has negative earnings. It offers ForeCYTE Breast Aspirator and FullCYTE Breast Aspirator, which collects specimens of nipple aspirate fluid for cytological testing at a laboratory; and a transport kit to assist with the packaging and transport of NAF samples to a laboratory, as well as makes and sells various medical devices primarily consisting of tools to assist breast surgeons.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.